Losartan, pembrolizumab and radiation for advanced head & neck cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a combination of three treatments—a blood pressure drug (losartan), an immunotherapy (pembrolizumab), and targeted radiation—for people with head and neck cancer that has come back, spread to a few spots, or is not responding to other treatments. The goal is to see if this mix can shrink tumors and help patients who have few options left.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have squamous cell carcinoma of the head and neck that has come back, spread to no more than 4 spots, or is not responding to treatment, and surgery cannot cure it.
- Your tumor can be safely biopsied (a small sample taken) and you agree to have that done during the study.
- Your cancer cells have a protein called PD-L1 at a level above 1% (CPS > 1%).
- You are 18 or older, in fairly good overall health (able to do daily activities), and have adequate kidney and liver function.
- You have not had an immunotherapy drug like Keytruda (pembrolizumab) before, and you have not had chemotherapy or radiation within the last 3-6 weeks.
- You are not currently taking certain blood pressure medications (like losartan, ACE inhibitors, or ARBs) and do not have active autoimmune disease or serious infections.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a targeted internal radiation treatment (DaRT) combined with pembrolizumab (an immune therapy) can shrink recurrent or metastatic head and neck squamous cell cancer that cannot be fully removed with surgery. It may help by making cancer more visible to the immune system while delivering localized radiation to a tumor area.
This trial studies whether adding pembrolizumab (an immune system medicine) to radiation can improve outcomes in people newly diagnosed with metastatic head and neck squamous cell cancer. It may help the immune system better recognize and fight the cancer alongside radiation.
This Phase 3 trial studies whether adding pembrolizumab (an immune medicine) to focused radiation (SABR) can better control head and neck cancer that has spread to only 1–5 spots. It may help some people live longer or delay cancer worsening by treating both the immune system and the specific metastases.
This trial tests a new combination for people whose head and neck cancer has come back after prior radiation. You'll receive an immunotherapy drug (pembrolizumab) plus radiation, then surgery. The goal is to see if this approach can improve how well surgery works.
This trial tests whether combining radiation therapy with immunotherapy works better than immunotherapy alone for advanced head and neck cancer that hasn't been treated before. The goal is to help your body's immune system fight the cancer more effectively.
This trial tests a combination of re-radiation and chemotherapy with the immunotherapy drug pembrolizumab for people whose head and neck cancer has come back after earlier treatment. It compares this approach to standard immunotherapy or chemo-immunotherapy, and may offer a new option for patients whose cancer has a specific marker (PD-L1).
Hear when a new Locally Recurrent Head and Neck Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.